{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:02:37Z","timestamp":1792058557218,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Hanma Investment Group Co., Ltd."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Environmental Toxicology and Pharmacology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.etap.2019.103202","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:59:17Z","timestamp":1559235557000},"page":"103202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model"],"prefix":"10.1016","volume":"70","author":[{"given":"Chen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanran","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.etap.2019.103202_bib0005","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-017-3387-5","article-title":"A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics","volume":"80","author":"Badowski","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.etap.2019.103202_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12031-018-1154-7","article-title":"Pharmacological Comparisons Between Cannabidiol and KLS-13019","volume":"66","author":"Brenneman","year":"2018","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.etap.2019.103202_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00269","article-title":"Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders","volume":"8","author":"Campos","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0020","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"59","key":"10.1016\/j.etap.2019.103202_bib0025","article-title":"The mouse forced swim test","author":"Can","year":"2012","journal-title":"Jove-J. Visual. Exp."},{"issue":"9","key":"10.1016\/j.etap.2019.103202_bib0030","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/15563650.2016.1209761","article-title":"Characterization of edible marijuana product exposures reported to United States poison centers","volume":"54","author":"Cao","year":"2016","journal-title":"Clin. Toxicol."},{"issue":"8-9","key":"10.1016\/j.etap.2019.103202_bib0035","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","article-title":"HYPNOTIC AND ANTI-EPILEPTIC EFFECTS OF CANNABIDIOL","volume":"21","author":"Carlini","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.etap.2019.103202_bib0040","unstructured":"CBD-OS for the treatment of Lennox-Gastaut syndrome and Dravet syndrome FDA advisory committee meeting briefing document."},{"key":"10.1016\/j.etap.2019.103202_bib0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejps.2017.07.003","article-title":"The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model","volume":"109","author":"Cherniakov","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.etap.2019.103202_bib0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1023\/A:1011980432646","article-title":"Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol","volume":"15","author":"Cox","year":"1998","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0055","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1871527313666140612114838","article-title":"Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa","volume":"13","author":"de Mello Schier","year":"2014","journal-title":"Cns & Neurol. Disorders-Drug Targets"},{"issue":"7","key":"10.1016\/j.etap.2019.103202_bib0060","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.etap.2019.103202_bib0065","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.etap.2019.103202_bib0070","series-title":"World Health Organization","author":"Depression","year":"2018"},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0075","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.etap.2019.103202_bib0080","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.etap.2019.103202_bib0085","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.etap.2019.103202_bib0090","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of Delta(9)-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1","key":"10.1016\/j.etap.2019.103202_bib0095","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2353\/ajpath.2006.050500","article-title":"Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes","volume":"168","author":"El-Remessy","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.etap.2019.103202_bib0100","series-title":"Delay of the Antidepressant Effect: Clinical Studies]","author":"Escande","year":"1995"},{"issue":"8","key":"10.1016\/j.etap.2019.103202_bib0105","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.bjp.0707337","article-title":"Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1 beta and iNOS expression","volume":"151","author":"Esposito","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0110","first-page":"582","article-title":"Fat emulsion vehicle for Intravenous Administration of an aqueous insoluble drug","volume":"32","author":"Fortner","year":"1975","journal-title":"Am. J. Hosp. Pharm."},{"issue":"4","key":"10.1016\/j.etap.2019.103202_bib0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.etap.2019.103202_bib0120","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1208\/s12249-010-9526-5","article-title":"Injectable lipid emulsions-advancements, opportunities and challenges","volume":"11","author":"Hippalgaonkar","year":"2010","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.etap.2019.103202_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(98)00040-0","article-title":"Microglia-specific localisation of a novel calcium binding protein, Iba1","volume":"57","author":"Ito","year":"1998","journal-title":"Mol. Brain Res."},{"issue":"3","key":"10.1016\/j.etap.2019.103202_bib0130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0896-6273(00)81122-8","article-title":"Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I","volume":"24","author":"Janz","year":"1999","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0135","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0006-2952(79)90358-7","article-title":"Pharmacokinetic fate of CANNABIDIOL and its relationship to barbiturate sleep time","volume":"28","author":"Karler","year":"1979","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.etap.2019.103202_bib0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1373\/clinchem.2010.152439","article-title":"Plasma cannabinoid pharmacokinetics following controlled oral Delta(9)-Tetrahydrocannabinol and oromucosal Cannabis extract administration","volume":"57","author":"Karschner","year":"2011","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0145","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/mp.2013.155","article-title":"Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis","volume":"19","author":"Kreisel","year":"2014","journal-title":"Mol. Psychiatry"},{"issue":"1-2","key":"10.1016\/j.etap.2019.103202_bib0150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nbd.2004.11.009","article-title":"Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson\u2019s disease","volume":"19","author":"Lastres-Becker","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.etap.2019.103202_bib0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2016.03.005","article-title":"Cannabidiol and epilepsy: rationale and therapeutic potential","volume":"107","author":"Leo","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.etap.2019.103202_bib0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.etap.2019.103202_bib0165","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","article-title":"Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans","volume":"9","author":"Manini","year":"2015","journal-title":"J. Addict. Med."},{"issue":"Suppl A","key":"10.1016\/j.etap.2019.103202_bib0170","doi-asserted-by":"crossref","first-page":"15A","DOI":"10.1155\/2005\/242516","article-title":"Pharmacokinetics of cannabinoids","volume":"10","author":"McGilveray","year":"2005","journal-title":"Pain Res. Manag."},{"issue":"3936","key":"10.1016\/j.etap.2019.103202_bib0175","doi-asserted-by":"crossref","DOI":"10.1126\/science.168.3936.1159","article-title":"Marihuana Chemistry","volume":"168","author":"Mechoulam","year":"1970","journal-title":"Science (New York, NY)"},{"issue":"4","key":"10.1016\/j.etap.2019.103202_bib0180","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.etap.2019.103202_bib0185","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pnpbp.2016.11.005","article-title":"Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia","volume":"75","author":"Mori","year":"2017","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.etap.2019.103202_bib0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2990.2012.01306.x","article-title":"Review: microglia of the aged brain: primed to be activated and resistant to regulation","volume":"39","author":"Norden","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"9","key":"10.1016\/j.etap.2019.103202_bib0195","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/03639041003657295","article-title":"Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers","volume":"36","author":"Paudel","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"11","key":"10.1016\/j.etap.2019.103202_bib0200","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00228-018-2516-3","article-title":"Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study","volume":"74","author":"Pellesi","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.etap.2019.103202_bib0205","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","article-title":"Emerging strategies for exploiting cannabinoid receptor agonists as medicines","volume":"156","author":"Pertwee","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"25","key":"10.1016\/j.etap.2019.103202_bib0210","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.jacc.2010.07.033","article-title":"Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy","volume":"56","author":"Rajesh","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.etap.2019.103202_bib0215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jpba.2018.07.004","article-title":"Simultaneous quantification of cannabinoids tetrahydrocannabinol, cannabidiol and CB1 receptor antagonist in rat plasma: An application to characterize pharmacokinetics after passive cannabis smoke inhalation and co-administration of rimonabant","volume":"160","author":"Ravula","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0220","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/01.wnl.0000176753.45410.8b","article-title":"Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis","volume":"65","author":"Rog","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.etap.2019.103202_bib0225","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.etap.2019.103202_bib0230","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tips.2016.12.004","article-title":"Cannabidiol claims and misconceptions","volume":"38","author":"Russo","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.etap.2019.103202_bib0235","article-title":"Cannabidiol induces rapid and sustained antidepressant-like effects through increased BDNF signaling and synaptogenesis in the prefrontal cortex","author":"Sales","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.etap.2019.103202_bib0240","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bbr.2016.01.033","article-title":"Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors","volume":"303","author":"Sartim","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.etap.2019.103202_bib0245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.drugalcdep.2018.02.022","article-title":"The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration","volume":"187","author":"Schlienz","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.etap.2019.103202_bib0250","doi-asserted-by":"crossref","DOI":"10.1007\/s40263-018-0550-4","article-title":"Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system","author":"Schonhofen","year":"2018","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.etap.2019.103202_bib0255","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ptr.2625","article-title":"Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders","volume":"23","author":"Scuderi","year":"2009","journal-title":"Phytother. Res."},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0260","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bdj.2007.749","article-title":"Cannabis; adverse effects from an oromucosal spray","volume":"203","author":"Scully","year":"2007","journal-title":"Br. Dent. J."},{"issue":"8","key":"10.1016\/j.etap.2019.103202_bib0265","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1523\/JNEUROSCI.22-08-03251.2002","article-title":"Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression","volume":"22","author":"Shirayama","year":"2002","journal-title":"J. Neurosci."},{"issue":"10125","key":"10.1016\/j.etap.2019.103202_bib0270","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.etap.2019.103202_bib0275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s002130050456","article-title":"Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation","volume":"134","author":"Willner","year":"1997","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.etap.2019.103202_bib0280","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000087097","article-title":"Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS","volume":"52","author":"Willner","year":"2005","journal-title":"Neuropsychobiology"},{"issue":"6","key":"10.1016\/j.etap.2019.103202_bib0285","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1172\/JCI59901","article-title":"Estrogen promotes Leydig cell engulfment by macrophages in male infertility","volume":"124","author":"Yu","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.etap.2019.103202_bib0290","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.etap.2019.103202_bib0295","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jpba.2015.05.019","article-title":"Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and Delta(9)-tetrahydrocannabinol in rat plasma","volume":"114","author":"Zgair","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"5","key":"10.1016\/j.etap.2019.103202_bib0300","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J. Psychopharmacol."}],"container-title":["Environmental Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668919300687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668919300687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T10:25:17Z","timestamp":1568888717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1382668919300687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":60,"alternative-id":["S1382668919300687"],"URL":"https:\/\/doi.org\/10.1016\/j.etap.2019.103202","relation":{},"ISSN":["1382-6689"],"issn-type":[{"value":"1382-6689","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model","name":"articletitle","label":"Article Title"},{"value":"Environmental Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.etap.2019.103202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103202"}}